HAYA Therapeutics is developing a proprietary anti-fibrotic therapy for myocardial fibrosis and heart failure by targeting a master regulator of fibrosis in the heart, Wisper. Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. HAYA will also implement a target discovery engine to develop a pipeline of lncRNA anti-fibrotic targets in multiple tissues/indications.